Ipamorelin: Research Overview

The short version

Ipamorelin is a small, lab-made peptide — just five amino acids — that activates the same receptor the stomach hormone ghrelin normally uses, called the ghrelin receptor or GHS-R1a. Activating that receptor on pituitary cells triggers a pulse of growth hormone release. What made ipamorelin notable when it was first characterized is what it does not do: earlier growth-hormone-releasing peptides also raised cortisol and prolactin as a side effect of receptor activation, and ipamorelin largely does not, even at high doses in animal studies.

Human research on ipamorelin is thin. Its only placebo-controlled human trial tested it for a surgical-recovery use and did not meet its main goal. It has never been approved by any regulator and is sold only as a research chemical. This page covers what that trial and the surrounding pharmacology actually found, what research-use communities report anecdotally, and the safety questions raised by chronic use of a ghrelin-receptor agonist.

What it is

Ipamorelin's full sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 — a synthetic pentapeptide built with an unusual amino acid (alpha-aminoisobutyric acid, or Aib) at one end and two D-amino acids (mirror-image forms not typically found in natural proteins) that make it resistant to the enzymes that would otherwise break it down quickly. It was derived from an earlier, less selective compound called GHRP-1 by removing a two-amino-acid segment from its middle.

Pharmacologically, it is classified as a growth hormone secretagogue and, more specifically, a selective agonist of the ghrelin receptor (GHS-R1a) — the same receptor the natural hunger hormone ghrelin activates.

How it works

Ipamorelin binds GHS-R1a on pituitary somatotroph cells — the same cell type CJC-1295 and tesamorelin act on, but through a completely different receptor and a different intracellular signal (calcium rather than cyclic AMP). That binding triggers a discrete pulse of growth hormone release. Because this pathway is mechanistically independent of the GHRH-receptor pathway, ipamorelin is often studied and used alongside GHRH analogs — the logic behind the CJC-1295/Ipamorelin combination discussed elsewhere on this guide.

Beyond the pituitary, GHS-R1a is also expressed on enteric and vagal neurons (relevant to gut motility), on pancreatic islet cells, and in hypothalamic appetite circuitry — the receptor-level explanation for why ghrelin-receptor agonists as a class tend to increase appetite, a pattern that shows up in ipamorelin's own real-world reports below.

What the research shows

The most recent published ipamorelin study, from 2024, tested it in ferrets alongside a related compound to see whether ghrelin-receptor agonism could counteract chemotherapy side effects. Ipamorelin reduced cisplatin-induced weight loss by roughly 24% during the delayed phase (48-72 hours after chemotherapy) but had no anti-emetic (anti-nausea) effect, in contrast to the comparison compound, which reduced acute vomiting by 60% through a separate mechanism ^[11].

The only controlled human trial of ipamorelin is a Phase 2 study in 114 adults recovering from bowel resection surgery, who received 0.03 mg/kg intravenously twice daily for up to a week. The trial's primary goal — shortening time to the first tolerated meal — was not met: 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance. Adverse events were, if anything, less frequent with ipamorelin (87.5%) than placebo (94.8%) ^[13]. The only human pharmacokinetic data come from an earlier study in eight healthy male volunteers, which found dose-proportional kinetics, a terminal half-life of about two hours, and a growth-hormone response peaking around 40 minutes after dosing ^[14].

Preclinical work adds two more data points: in rats, daily subcutaneous ipamorelin dose-dependently increased longitudinal bone-growth rate without changing total IGF-1 or bone-turnover markers, suggesting a partly local, GH-pulse-driven skeletal effect rather than a purely IGF-1-mediated one ^[15]. And a 2015 safety-pharmacology study of a different, related ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats after 28 days of dosing — ipamorelin itself was not the compound tested, but the finding is treated in the literature as a class-level signal worth keeping in mind for any chronic ghrelin-receptor agonist ^[12].

Reported effects, cautions & safety

Reported effects (anecdotal, not clinical evidence): deeper, more restorative sleep is consistently the most-cited benefit in research-use community reports, often noticed within the first one to two weeks. Vivid dreams, especially early in use, are also frequently mentioned and generally described as settling down as sleep patterns stabilize. None of this comes from a controlled trial.

On the downside, a brief facial flush or "head rush" in the 5 to 15 minutes after injecting is widely reported, often compared to a niacin flush, along with occasional tingling or numbness in the hands and feet. Community reports also describe increased appetite (consistent with the ghrelin-receptor mechanism above), mild water retention, injection-site irritation, and — after several months of continuous use — a sense that effects fade, which the community generally addresses with on/off dosing cycles.

Cited safety cautions: because GH stimulates the liver to produce IGF-1, a known driver of cell proliferation, researchers flag active or recent malignancy as a mechanism-based concern; ipamorelin's own founding characterization established that it potently releases GH, and this reasoning is class-level rather than drawn from any ipamorelin-specific cancer study ^[15]. Ghrelin-receptor agonists as a class also activate hypothalamic appetite centers, and researchers note this as a caution for anyone for whom increased appetite or fat gain would be clinically harmful. On the cardiovascular side, the most direct safety signal in the literature is preclinical: a 28-day study of a related (not identical) ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats, a class-level finding that keeps chronic ghrelin-receptor agonism under scrutiny even though no equivalent long-duration study of ipamorelin itself exists ^[12]. Beyond the single Phase 2 surgical trial and the small pharmacokinetic study, there is no long-term human safety database for ipamorelin ^[13][14], and research-grade material from unregulated suppliers carries no pharmaceutical quality assurance. One comparative point favors ipamorelin specifically: unlike older, less selective GH-releasing peptides, it does not meaningfully raise cortisol or prolactin even at high doses in animal studies — a genuine, mechanism-grounded safety advantage relative to its predecessors, though not a claim that it has no other effects ^[15].

Where it fits in the Growth Hormone Axis

Ipamorelin supplies the ghrelin-receptor half of the mechanism map on this guide — distinct from the GHRH-receptor route that CJC-1295 and tesamorelin use. That independence is exactly why it shows up combined with CJC-1295 in CJC-1295/Ipamorelin, the most-discussed protocol in this space. Its selectivity for GH release over cortisol and prolactin is its most distinctive research finding relative to older secretagogues. See how it stacks up against the other three on the comparison page.